ROIX — Response Oncology Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro Cap

Annual income statement for Response Oncology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	1997 December 31st	C1998 December 31st	C1999 December 31st	2000 December 31st	2001 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K405	10-K405	10-K405	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	102	128	136	131	118
Cost of Revenue
Gross Profit	52.8	61	55.4	41.4	28.2
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	94.6	161	136	152	172
Operating Profit	7.37	-32.4	-0.829	-21.1	-53.7
Total Net Non Operating Interest Income / Expense
Net Income Before Taxes	6.78	-33.2	-1.53	-21.7	-53.9
Provision for Income Taxes
Net Income After Taxes	4.2	-17.4	-1.69	-14.4	-51.4
Net Income Before Extraordinary Items
Net Income	4.2	-17.4	-1.69	-14.4	-51.4
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	4.2	-17.4	-1.69	-14.4	-51.4
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.36	0.467	-0.037	-0.33	-1.59
Dividends per Share